AbbVie (ABBV) Income from Continuing Operations (2012 - 2026)
AbbVie (ABBV) posted quarterly Income from Continuing Operations of 697000000.0 for Q1 2026, down 45.93% year-over-year from 1289000000.0 in Q1 2025, and down 61.6% quarter-over-quarter from 1815000000.0 in Q4 2025.
AbbVie (ABBV) Income from Continuing Operations (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Income from Continuing Operations for 15 consecutive years, with 697000000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 45.93% year-over-year to 697000000.0; the TTM figure through Mar 2026 stood at 3641000000.0 (down 13.37% YoY), while the FY2025 annual figure was 4233000000.0, down 1.24% from the prior year.
- Income from Continuing Operations fell to 697000000.0 in Q1 2026 per ABBV's latest filing, from 1815000000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 4493000000.0 in Q1 2022 and bottomed at 97000000.0 in Q1 2023.
- Historically, Income from Continuing Operations has averaged 1505647058.82 across 5 years, with a median of 1372000000.0 in 2024.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 102.79% — and 2025, when it surged 7991.3%.
- AbbVie's Income from Continuing Operations stood at 2472000000.0 in 2022, then slumped by 66.67% to 824000000.0 in 2023, then sank by 102.79% to 23000000.0 in 2024, then soared by 7991.3% to 1815000000.0 in 2025, then plunged by 61.6% to 697000000.0 in 2026.
- Business Quant data shows ABBV's Income from Continuing Operations at 697000000.0 in Q1 2026, 1815000000.0 in Q4 2025, and 188000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 17.71 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.62 Bn |
| Mar 31, 2026 | 697.00 Mn |
| Dec 31, 2025 | 1.82 Bn |
| Sep 30, 2025 | 188.00 Mn |
| Jun 30, 2025 | 941.00 Mn |
| Mar 31, 2025 | 1.29 Bn |
| Dec 31, 2024 | -23.00 Mn |
| Sep 30, 2024 | 1.56 Bn |
| Jun 30, 2024 | 1.37 Bn |
| Mar 31, 2024 | 1.37 Bn |
| Dec 31, 2023 | 824.00 Mn |
| Sep 30, 2023 | 1.78 Bn |
| Jun 30, 2023 | 2.03 Bn |
| Mar 31, 2023 | -97.00 Mn |
| Dec 31, 2022 | 2.47 Bn |
| Sep 30, 2022 | 3.95 Bn |
| Jun 30, 2022 | 928.00 Mn |
| Mar 31, 2022 | 4.49 Bn |
| Dec 31, 2021 | 4.05 Bn |
| Sep 30, 2021 | 3.18 Bn |